

FRANSMAL: Translational research ervices for accelerated discovery of antimalarial drugs

Iñigo Angulo Barturen, PhD CEO

13th January 2020, Bilbao









The company

The Art of Discovery

In vivo evaluation of antimalarial drugs in humanized mice







INDUSTRIALIZED PK/PD STUDIES IN HUMANIZED MICE

Study single drugs and combinations of new treatments to optimize efficacy

- Intensive exploration of PK/PD space
- Impact of resistant genotypes
- High precision/predictivity
- Rapid assessment
- Human pathogens

Machine Learning-Integrated Multivariate PK/PD Priors for human efficacy

 Efficacious concentration
Time of exposure
Impact of resistant genotypes

Hypothesis testing


A TOOL to inform OPTIMAL DESIGN on treatment for

Human Challenge Model

Clinical trials

- Hypothesis-driven experimental design
- Increased precision
- More statistical power
- Maximize information content from human studies

The Art of Discovery





The BIC Bizkaia center hosts TAD facilities.

The BIC Bizkaia is specifically aimed at promoters and startups and is operating since October 2014.







State-of-the-art animal facility to host highly immunodeficient mice



New *state-of-theart* insectary to host infected mosquitoes

UNOVARTIS

MERCK

uch

BILL& MELINDA GATES foundation









JT SOUTHWESTERN MEDICAL CENTER

The consortium

TROPIC HEALTH



https://tropiq.nl/

- established in 2011, unique focus on global health and vector borne infectious diseases
- combines **world class parasitology and entomology** with state-of-the art drug discovery technologies
- current headcount: 18 (30% PhD)







https://www.theartofdiscoverysl.com

- established in 2016, focus on <u>global health and in vivo</u> <u>translational pharmacology</u> in humanized mouse models
- combines world class expertise in preclinical pharmacology in humanized mouse models with state-of-the art drug discovery technologies
- current headcount: 10 (40% PhD)


TRANSMAL aims at **implementing a commercial, fee-forservice platform** for cost-effective evaluation of the efficacy of antimalarial drugs.

The development of such treatments is key to meet the goal of global malaria elimination, but hampered by a <u>lack of predictive</u> <u>pre-clinical models with sufficient throughput and level of standardization</u>.

TRANSMAL will deliver enabling technology in the form of **industrial-quality in vitro and in vivo models to predict the efficacious dose of candidate drugs**.







ANNEX 2: TRANSMAL TIME-ACTIVITY CHART

WP	Activity	Task	Partner			
1. Pa	rasite produ	uction and preservation methods				
	1.1 Game	tocyte preservation				
		1.1a test different methods in relation to gametocyte viability	TropIQ			
		1.1b address infectivity to mosquitoes	TropIQ			
	1.2 Spore	zoite preservation				
		1.2a test different methods in relation to sporozoite viability	TropIQ			
		1.2b address in vitro infectivity to human hepatocytes	TropIQ			
2 In v	vivo gameto	cytaemia				
	2.1 Estab	lish in vivo gametocytaemia				
		2.1a establish bone marrow transplantation	TAD			
		2.1b evaluate endogenous gametocyte maturation	TAD			
		2.1c produce in vitro gametocytes	TropIQ			
		2.1d evaluate engraftment of stage V gametocytes	TAD			
	2.2 Evalu	ate infectivity of engrafted mice				
		2.2a SMFA on cryopreserved blood	TropIQ			
	2.2b direct feeding on engrafted mice					
3. PK	/PD malaria	transmission-blocking assay development				
	3.1 transi	mission PK-PD model				
		3.1a establish in vitro PD model	TropIQ			
		3.1b Industrial in vivo assay development: compound dosing and PK	TAD			
		3.1c Industrial in vivo assay development: ex vivo and in vivo efficacy (PD) analyses	TropIQ			
4. In	vivo liver ar	nd secondary blood parasitaemia				
	4.1 Estab	lish humanized mouse model				
	4.1a produce sporozoites					
		4.1b Kinetics of liver and peripheral blood infection in sporozoite-	TAD			
		infected HH-engrafted mice	TAD			
5 PK/	PD malaria	liver stage assay development				
	5.1 liver s	tage PK-PD model				
		5.1a establish in vitro PD model	TropIQ			
		5.1b Industrial in vivo assay development: compound dosing and PK	TAD			
		5.1c Industrial in vivo assay development: ex vivo and in vivo efficacy (PD) analyses	TAD			

A challenging project with a high scientific and logistical complexity





Centro para e Desarrollo

Tecnológico

@CDTIoficial

MINISTERIO DE CIENCIA, INNOVACIÓN Y UNIVERSIDADES



PROJECT OVERVIEW

E - TRANSMAL

Translational research services for accelerated discovery of antimalarial drugs

Time to completion 24 months Total cost for all parts 2,378,747 €

TECHNICAL AREA BIOLOGICAL SCIENCES / TECHNOLOGIES > Medical technology > Pharmaceutical Products / Drugs

MARKET AREA

MEDICAL / HEALTH RELATED > Other Medical / Health Related > Pharmaceuticals/fine chemicals

PARTICIPANT NAME	ROLE	COUNTRY	ORGANISATION TYPE	TOTAL COST
TropIQ Health Sciences	Main	THE NETHERLANDS	R and D Performing SME	1,100,000 €
The Art of Discovery S.L.	Partner	SPAIN	R and D Performing SME	1,278,747 €



The experience

EuroStars is an excellent tool to promote international cooperation among European companies because of the intensity and type of funding and its flexibility on the type of partnerships funded.

The support provided by EuroStars and, particularly, CDTI professionals is superb.

The EuroStars program is a fantastic opportunity to prepare for more ambitious projects.



The likelihood of being awarded and the intensity of the funding may heavily depend on the country(ies) of partner organizations.


The local project depend of the funding by agencies of its national government. The criteria of funding may be different.

EuroStars is organized as two-projects in one:

- Duplication of submissions (EuroStars and InterEmpresas).
- Proposals and reporting in two languages: English and Spanish
- Reporting every 6 months in duplicate (Eureka and CDTI)

No funding for project management.

There is a risk of lack of effective cooperation.



Address all the tasks to **prepare your proposal with sufficient time**.

Pay attention to the criteria of funding activities for InterEmpresas. Make sure that all the activities in your workplan meet the rules of funding!!!

The business case, market analysis and marketing plan are essential pieces of the proposal.

Pay attention to the agreement between partners. Unexpected difficulties might appear during the negotiations!





Be resilient and ...good luck!